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Summary  
To further investigate the use of DNA repair-enhancing agents for skin cancer prevention, we treated 
Cdk4R24C/R24C/NrasQ61K mice topically with the T4 endonuclease V DNA repair enzyme (known as 
Dimericine) immediately prior to neonatal ultraviolet radiation (UVR) exposure, which has a powerful 
effect in exacerbating melanoma development in the mouse model. Dimericine has been shown to reduce 
the incidence of basal-cell and squamous cell carcinoma. Unexpectedly, we saw no difference in 
penetrance or age of onset of melanoma after neonatal UVR between Dimericine-treated and control 
animals, although the drug reduced DNA damage and cellular proliferation in the skin. Interestingly, 
epidermal melanocytes removed cyclobutane pyrimidine dimers (CPDs) more efficiently than surrounding 
keratinocytes. Our study indicates that neonatal UVR-initiated melanomas may be driven by mechanisms 
other than solely that of a large CPD load and/or their inefficient repair. This is further suggestive of 
different mechanisms by which UVR may enhance the transformation of keratinocytes and melanocytes. 
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Significance  
The results of Dimericine treatment in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) 
have led to much discussion about the potential use of DNA repair-enhancing agents in skin cancer 
prevention. The development of “super-sunscreens” that in addition to shielding the skin from ultraviolet 
radiation (UVR) also contain active compounds that function to enhance DNA repair of damaged 
“sunburnt” cells, is underway. We have used the Cdk4R24C/R24C/NrasQ61K mouse model to test how enhanced 
repair of DNA following UVR will impact on the development of melanoma and found that it had no 
effect. Our findings argue that DNA repair enhancement may not be helpful, at least for some types of 
melanoma, and are suggestive of potentially different mechanisms of UVR carcinogenesis between 
melanocytes and keratinocytes.  
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Introduction 
Exposure to solar ultraviolet radiation (UVR) is the main environmental risk factor for melanoma 
development. The precise mechanism by which sunlight induces melanoma is still unclear, however sun 
exposure can cause the generation of various types of cellular and DNA damage, immune suppression, and 
inflammation (Abdel-Malek et al., 2008). The importance of effective DNA repair is highlighted in patients 
with the rare genetic disease xeroderma pigmentosum (XP), in which a defect in DNA repair is associated 
with the development of melanoma and other skin cancers much earlier in life and with increased risk 
compared to the general population (Kraemer et al., 1994). Tanaka et al (1975)-  first showed that treating 
XP cells in culture with the bacterial DNA excision repair enzyme T4 endonuclease V reduced DNA 
damage induced by UVR. Further clinical studies have demonstrated that the repair enzyme encapsulated in 
a liposomal delivery vehicle can be transported to intracellular compartments of human and mouse skin 
(Wolf et al., 2000, Yarosh et al., 1992). The hydrophobicity afforded by the liposomal complex allows for 
the penetration of the enzyme through the stratum corneum, delivering T4 endonuclease V to epidermal 
keratinocytes (Yarosh et al., 1994). The T4 endonuclease V protein lacks a nuclear localization sequence 
(NLS), entering the nucleus through passive diffusion after initially accumulating in the cytoplasm of cells 
(Yarosh et al., 1994). 
 Once inside the nucleus, T4 endonuclease V, a T4 pyrimidine dimer glycosylase, acts on 
cyclobutane pyrimidine dimers (CPDs). The enzyme scans through DNA, specifically binding to any 
CPDs.  Upon recognition of a CPD, it bends the duplex DNA and rotates the nucleotide base 
complementary to the 5' residue of the CPD, resulting in a cleavage event and base excision of the dimer 
(Morikawa and Shirakawa, 2000). It is likely that an exonuclease degrades the area surrounding the single-
strand break, and a polymerase fills in the gap, however the precise mechanism downstream of T4 
endonuclease V is unclear. 
  Topical application of the T4 endonuclease V liposome lotion (known as Dimericine) accelerated 
the removal of UVR-induced DNA damage in XP patients and reduced the rate of actinic keratoses and 
basal-cell carcinoma (BCC) (Yarosh and Klein, 1996, Yarosh et al., 2001). Dimericine has also been shown 
to reduce the incidence of squamous cell carcinoma (SCC) in UVR exposed SKH-1 hairless mice (Yarosh 
et al., 1992). We established a mouse model of melanoma using transgenic animals carrying a melanocyte-
specific Nras activating mutation and the cell cycle-deregulating Cdk4 R24C mutation (Hacker et al., 
2006). Exposing these mice to a single neonatal dose of UVR greatly increased melanoma penetrance in 
this model. The aim of this study was to determine whether treatment with Dimericine would prevent, or 
reduce, UVR-induced melanoma development in this model.  
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Results 
Dimericine treatment reduced the level of DNA damage following UVR exposure 
Topical Dimericine treatment 30 minutes prior to UVR exposure reduced the level of DNA damage 
present in mouse epidermal keratinocytes after a single neonatal UVB dose of 5.9 kJ/m2. Evidence of 
significant erythema (peeling) was observed 72 h after UVR in placebo-treated, but not in Dimericine-
treated animals (Figure S1). We observed only a relatively small amount of 6-4 photoproduct damage in the 
epidermis at 3 h post-UVR, with an average of only 7.5% and 3.4% of cells staining in placebo-treated 
(n=3) and Dimericine-treated (n=3) animals respectively (Mann Whitney p=0.014) (Figure 1A and 2A). 
We observed no evidence of 6-4 photoproducts in non-UVR treated animals (Figure 1A).  The majority of 
6-4 photoproducts were removed by 24 h in both placebo and Dimericine treated animals (data not shown). 
We rarely observed any melanocytes harbouring 6-4 photoproducts and found no significant difference 
between Dimericine +UVR treated animals and placebo treated animals. 
Dimericine treatment significantly reduced the percentage of epidermal cells harbouring CPDs 
post-UVR, the greatest difference between Dimericine and placebo treated animals was observed at the 3 h 
post-UVR timepoint (Mann Whitney p= 0.004)(Figure 1B). No CPDs were observed in the epidermis of 
non-UVR treated animals (data not shown). We analysed 128 epidermal melanocytes from three placebo 
+UVR treated animals and found that at 3 h after UVR 92% carried CPDs while in the Dimericine +UVR 
cohort (n=3) we analysed 87 epidermal melanocytes and found that only 59% carried CPDs (Pearson Chi-
Squared p<0.001)(Figure 2B). Dimericine treatment also reduced the number of extra-follicular dermal 
melanocytes carrying CPDs at 3 h post-UVR, with 36% of 330 melanocyte harbouring CPD damaged 
compared with 75% of 260 extra-follicular melanocytes in placebo treated animals (Pearson Chi-Squared 
p<0.001). These results suggest that Dimericine penetrates the skin and reduces DNA damage in 
melanocytes in the epidermis and dermis. Interestingly, even without Dimericine CPDs were undetectable 
in both epidermal and extra-follicular melanocytes by 24 h post-UVR. In contrast, epidermal keratinocytes 
(both basal and suprabasal) still exhibited CPD damage at 24 h post-UVR (Figure 1B). Dimericine sped up 
the initial removal of CPDs from these cells (at the 3 h timepoint), but by 24 h post UVR there was no 
significant difference in the level of CPDs between placebo and Dimericine treated animals. 
 
Proliferation of melanocytes inhibited by Dimericine treatment 
At 72 h post-UVR there was an increase in proliferating epidermal keratinocytes as measured by 
Ki67 positivity. Animals treated with placebo lotion (n=3) had on average 16% of epidermal cells (both 
basal and suprabasal keratinocytes) proliferating, while Dimericine-treated animals (n=4) had on average 
9% and non UVR-treated animals (n=3) only  4% of epidermal cells proliferating (Figure 3A and 2C). 
These differences are statistically significant (ANOVA, p<0.001), and post hoc analyses (Tukey’s test) 
revealed that all three means were statistically significantly different from each other. There was a higher 
percentage of epidermal melanocytes proliferating at 72 h post-UVR in placebo-treated animals (55%, 
133/241) compared with Dimericine-treated  (36%, 45/126) and non-UVR treated animals (24%, 8/25). 
Dimericine treatment significantly reduced the proliferation of epidermal melanocytes (Pearson chi squared 
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p<0.01). We also analysed Ki67 positivity of extra-follicular dermal melanocytes at 72 hours post-UVR 
and found no difference between animals treated with placebo +UVR  (26%, 63/247) and Dimericine 
+UVR (23%, 61/263) (Pearson chi squared p= 0.6). There were a higher percentage of hair follicle outer 
root sheath (ORS) melanocytes proliferating at 72 h post-UVR in placebo-treated animals (68%, 141/206) 
compared with Dimericine-treated (43%, 54/125) and non-UVR treated animals (31% , 35/112) (Pearson 
chi squared p<0.001). 
 
Migration of melanocytes to the epidermis following UVR exposure  
The numbers of epidermal melanocytes increased following UVR exposure and peaked at 72 h 
post-UVR (Figure 3B). Dimericine treatment prior to UVR resulted in a slight decrease in epidermal 
melanocyte number at 72 h post-UVR (Figure 2D and 2E). The average number of epidermal melanocytes 
per field reduced from 14.4 in placebo treated animals (n=3) to 9.3 in animals treated with Dimericine 
(n=4) (ANOVA contrast t-test p<0.01) (Figure 3B). In comparison the non-UVR cohort did not exhibit an 
increase in the number of epidermal melanocytes over the period of the experiment (Figure 3B).  
Dermal melanocytosis is part of the phenotype of animals carrying the melanocyte-specific Nras 
mutation (Ackermann et al., 2005). There was a much greater number of dermal extrafollicular 
melanocytes in Cdk4R24C/R24C/NrasQ61K mice compared to homozygous Cdk4R24C/R24C animals regardless of 
treatment regimen (Placebo + UVR, Dimericine + UVR or non-UVR) (Figure 3C). These differences were 
statistically significant between Cdk4R24C/R24C/NrasQ61K and homozygous Cdk4R24C/R24C animals (ANOVA 
p<0.01)(Figure 3C).  
 
Dimericine did not prevent melanoma development in Cdk4R24C/R24C/NrasQ61K mice 
Thirty-three percent of mice homozygous for the Cdk4-R24C mutation, and also carrying the melanocyte-
specific activated Nras mutation (Cdk4R24C/R24C/NrasQ61K), developed melanoma spontaneously by 250 days 
(Table 1). A single neonatal UVR treatment increased the tumour penetrance and significantly decreased 
the age of onset (Log rank test Bonferroni correction, p>0.001) (Table 1). We compared the penetrance of 
melanoma in Cdk4R24C/R24C/NrasQ61K mice, both with and without Dimericine treatment after a single 
neonatal UVR dose. We observed no statistically significant difference in the onset of melanoma 
development between the placebo + UVR and the Dimericine + UVR treated cohorts (Log rank test 
Bonferroni correction, Table 1). 
We observed no phenotypic or histopathological differences between lesions that developed after 
Dimericine and placebo treatment (Figure 4). Lesions were mainly dermal melanomas (Figure 4B and C). 
They were often multicentric, had aberrant nuclear features, and were positive for Tyrp-1 (Figure 4C and 
D). We did observe a number of melanocytes scattered along the basal layer near the tumour site and 
superficial dermal nests in adult Cdk4R24C/R24C/NrasQ61K animals regardless of UVR treatment (Figure 4D 
and E). We also assessed indicators of tumour aggressiveness. We saw no significant difference in the 
average number of lesions per animal between the non-UVR, +UVR, placebo +UVR and Dimericine 
+UVR treated cohorts (Table 2, Pearson’s Chi Squared p=0.09). Similarly, there was no difference in the 
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average size of lesions among animals treated with either +UVR, placebo +UVR and Dimericine +UVR 
(Figure 4F) (ANOVA p=0.37).  
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Discussion 
To further investigate the use of nucleotide excision repair (NER)-enhancing agents for skin cancer 
prevention after UVR exposure we treated mice topically with Dimericine immediately prior to neonatal 
UVR exposure, which has a powerful effect in exacerbating melanoma development in mouse melanoma 
models. Unexpectedly, we saw no difference in penetrance or age of onset of melanoma after neonatal UVR 
between Dimericine-treated and control animals. This is not the case for non-melanoma skin cancer 
induction in mice – which is significantly reduced after Dimericine treatments (Yarosh et al., 1992). Notably, 
chronic UVR is necessary for UVR-induced non-melanoma skin cancer induction in mice. This is normally 
ineffective in inducing melanoma, even in transgenic animals that are highly melanoma-prone after neonatal 
UVR (Larue and Beermann, 2007). Our results are further suggestive of different mechanisms of UVR 
tumorigenesis between the respective cell types (melanocytes vs keratinocytes) and possibly a different role 
for CPDs in melanoma induction after neonatal UVR than in SCC induction after repeated UVR exposures 
in mice. It is not known how well neonatal UVR in mice corresponds to settings whereby UVR may induce 
melanoma in humans, but it is suspected to be somewhat analogous to childhood sunburns.  
One caveat of this study is that we do not know the dose-responsiveness for melanoma induction 
after neonatal UVR in the model we have used (Cdk4R24C/R24C/NrasQ61K mice). For instance, melanoma may 
be induced by relatively low exposures that result in significantly lower levels of CPDs than the dose we 
delivered. However the work of De Fabo et al (2004), the only study so far to assess the role of different total 
UVB doses in neonatal UVR-induced melanoma, suggests that the relationship between UVB dose and 
melanoma induction is close to linear in the albino Hgf model. We suspect that non-linearity of response 
does not explain the lack of reduction in melanoma incidence in our study due to enhancement of DNA 
repair. Notably, in both this and our previous study, we do not see any evidence that the neonatal 
melanocytes in Cdk4R24C/R24C/NrasQ61K mice do not efficiently remove CPDs. In fact epidermal melanocytes 
remove CPDs more efficiently than surrounding keratinocytes. This would fit with the notion that up-
regulation by UVR of keratinocyte-derived cytokines (e.g. αMSH, EDN1, KITLG) results not only in 
stimulation of melanocyte melanin production, differentiation, and proliferation, but also in enhancement of 
their DNA repair capacity (Abdel-Malek et al., 2008).  Interestingly, we also noted that melanocytes were 
often present in the epidermal basal layer adjacent to tumours. It is unclear whether this effect is driven by 
changes in the keratinocytes adjacent the tumour, melanoma cells, or both.  
It was also interesting to note that treatment with Dimericine, which does not have any direct action 
on 6-4 photoproducts, did however reduce the amount of 6-4 damage.  It could be speculated that Dimericine 
shifts repair of CPDs into base excision repair from nucleotide excision repair by making a glycosylic bond 
break and releasing the 5’ pyrimidine base.  As nucleotide excision repair complexes have to repair both 
CPDs and 6-4 photoproducts.  When the NER is freed from the task of repairing CPDs, there is more 
available to focus on the 6-4 photoproducts, and the expected result would be somewhat faster repair. 
Additionally, this study has only examined global genomic repair in the skin following treatment with 
Dimericine and there may be effects related to transcription coupled repair that may exacerbate 
tumorigenesis. 
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Further complicating the interpretation of our results, other studies show that a defective NER 
response does enhance melanoma development in animals defective in both Ink4a and Arf. Ink4a/Arf-/-/Xpa-/- 
(van Schanke et al., 2006) and Ink4a/Arf-/-/Xpc-/- (Yang et al., 2007) mice develop melanoma with higher 
rates after neonatal UVR than for Ink4a/Arf-/- alone. The reason for the apparently contrasting results is not 
obvious. It could involve the germline mutations carried by the mice themselves. Our animals carried a 
germline cell cycle defect (Cdk4-R24C) and a melanocyte-specific Nras mutation at the time of UVR 
exposure - whereas in the other studies the animals did not have a prior Ras pathway mutation. Interestingly, 
in the Yang et al (2007) study Kras mutations were induced during tumorigenesis in many of the melanomas 
developing in the Ink4a/Arf-/-/Xpc-/- mice. Thus it is possible that one action of CPD photoproducts in 
melanomagenesis is to induce mutations in the genes that were already defective in the mice in our study 
(Cdk4 and Ras). Alternatively, defective NER signalling may exacerbate tumorigenesis in other ways in 
addition to simply resulting in defective removal of CPDs. These other mechanisms would not manifest in 
our study. Furthermore, as dimericine and placebo treated animals have the same initial levels of CPDs 
immediately post-UVR, the initial levels of CPDs and resultant burst of cytokine release within the skin, may 
be more important for melanomagenesis, than the length of time dimers are present.  
Another interpretation of our findings is that melanomagenesis after neonatal UVR is not simply due 
to the presence of CPDs generated by UVR exposure. Wolnicka-Glubisz et al., (2007) have previously 
shown that neonatal mice show a defective inflammatory response to UVR suggesting that damaged cells 
may not be properly recognised and targeted by the immune system and removed when necessary. In 
addition, other types of DNA (or other) damage such as oxidative lesions have been suggested to play a role 
in melanomagenesis after neonatal UVR. Notably, treatment of Hgf transgenic mice with antioxidants after 
neonatal UVR delayed the age of onset of melanoma (Cotter et al., 2007), which enhancement of NER did 
not do in our study. Another possible contributing factor to melanoma genesis after neonatal UVR is the 
proliferative and migratory response of neonatal melanocytes (Walker et al., 2008). This may contribute to 
their destabilisation and increase their risk of transformation. Our results reveal the importance of this 
response in melanocyte transformation as it was reduced by enhancement of NER using Dimericine, but still 
elevated compared to non-UVR treated animals. In connection with this melanocyte response, 
Cdk4R24C/R24C/NrasQ61K mice have dermal melanocytosis, which is not present in wild type mice. While 
epidermal melanocytes greatly increase in number after UVR exposure, interfollicular dermal melanocyte 
numbers in the melanoma-prone mice did not change. All of the  proliferative response is centred on the hair 
follicle, with melanocytes migrating upwards into the basal layer from the outer root sheath (ORS) after 
UVR exposure (Walker et al., 2008). This opens up the question as to from which population are the 
melanomas emanating, is it the proliferating epidermal/ORS melanocytes or the non-responding dermal 
population? In our model and most other mouse models melanomas appear to originate from the dermis. This 
would suggest that the proliferating melanocyte population may not be one from which the melanomas are 
initiated.  
In summary, treatment with Dimericine prior to UVR exposure reduced CPDs in mouse skin but did 
not protect against melanoma development. This finding indicates that UVR-induced melanomas are perhaps 
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driven by mechanisms other than solely that due to persistence of CPD-associated damage. 
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Methods 
All experiments were undertaken with the approval of the QIMR animal ethics committee (approval 
number A98004M). 
 
Mouse strains. 
Cdk4R24C/R24C mice have been previously described (Rane et al., 1999). Tyr-Nras (Q61K) transgenic 
mice express mutant (Q16K) Nras in a melanocyte-specific manner via a tyrosinase gene promoter/enhancer 
cassette previously described (Ackermann et al., 2005). All mice were on a FVB background. Diagnosis of 
melanoma was confirmed by a pathologist (HKM) and Tyrp-1 staining preformed to confirm melanocytic 
origin of the tumour cells, as previously described (Hacker et al., 2006). 
 
UVR and Dimericine treatments.  
At day 2 postnatal, animals were irradiated with a single UVR dose of 5.9 kJ/m2 as described 
previously (Walker et al., 2008). Animal received either the Dimericine liposome lotion or placebo lotion 30 
min prior to irradiation as previously described (Yarosh et al., 2001). Briefly, the Dimericine liposome lotion 
consisted of 1 mg/L T4 endonuclease V, encapsulated in liposomes, in a 1 % hydrogel lotion and the placebo 
lotion consisted of equivalent empty liposomes, without enzyme, in a 1% hydrogel lotion.  Animals used in 
the proliferation and DNA damage assays, were monitored and photos taken of each animal prior to 
euthanasia.  The same region of dorsal skin was taken from each animal (Figure S2). 
 
Proliferation and DNA damage immunofluorescent Assays. 
Paraffin-embedded sections of mice skins were dewaxed, and antigen retrieval performed using 
Dako retrieval solution, pH 6.0 (Dako, Glostrup, Denmark). Proliferating cells were detected using rat anti-
Ki67 (Dako, M7249) diluted 1/100 and melanocytes were identified using tyrosinase-related protein 1 
(Tyrp1, PEP1) rabbit polyclonal antibody diluted 1:400 (a gift from Dr V.J. Hearing, NIH, Bethesda).  
Biotinylated goat anti-rat secondary (Jackson ImmunoResearch laboratories, West Grove, USA) was used 
for Ki-67 detection with streptavidin linked Alexa-Fluor 488 (Invitrogen, Carlsbad, USA) and Tyrp1 was 
detected using donkey anti-rabbit Alexa-Fluor 555 (Invitrogen).  
Damaged cells were detected using mouse anti-thymine dimer (KTM53) (Kamiya biomedical 
company, Seattle, USA) diluted 1/200 and melanocytes were identified using Tyrp1 antibody diluted 1:400.  
A mouse-on-mouse block (Biocare medical, Concord, USA) was conducted for 30 min prior to O/N 
incubation with primary antibodies. Biotinylated donkey anti-mouse secondary (Jackson) were used for 
thymine dimmer (CPD) detection with streptavidin linked Alexa-Fluor 488 (Invitrogen) and Tyrp1 detected 
using donkey anti-rabbit Alexa-Fluor 555 (Invitrogen). Cells with 6-4 photoproducts were detected using 
mouse anti-6-4 photoproducts (64M-2) (Medical and biological laboratories, Nagoya, Japan) diluted 1/100 
and melanocytes were identified using Tyrp1 antibody diluted 1:400.  A mouse-on-mouse block (Biocare 
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medical) was conducted for 30 min prior to O/N incubation with primary antibodies. The same secondary 
detection system as the thymine dimer assay was used. 
All slides were cover-slipped using vectorshield-DAPI mounting media (Vector laboratories, 
Burlingame, USA). Images were captured using the DeltaVision Microscope system (Applied Precision, 
Issaquah, USA). The deltaVision tracking software and stage technology allowed non overlapping images to 
be collected along each skin section. Ten fields were counted using an x20 objective along a skin section 
from each animal for all assays but the ki67 staining which used 5 fields per animal.  The sampled fields 
were 300µm in length spaced one field apart and we did not select areas for specific cell types or staining 
patterns. Sections were counted using Image J (available: http://rsbweb.nih.gov/ij/index.html). All staining 
and quantification procedures were performed blind to the samples ID.  
 
Statistical Analysis 
The Prism software package (GraphPad Software, La Jolla, USA) was used to generate graphs and 
the SPSS v15 software package (SPSS, Illinois, USA) was used to perform statistical analyses. Statistical 
significance was p<0.05 and denoted by * in subsequent graphs.  Mann Whitney tests were performed to 
compare the average percentage of epidermal cells carrying DNA damaged amongst placebo and Dimericine 
treated groups. Pearson’s Chi squared tests were performed to compare the percentage of melanocyte 
populations harbouring CPD damage and proliferating amongst placebo and Dimericine treated cohorts. 
One-way ANOVAs were used to test for evidence of difference in: mean proliferative response 72 h post-
UVR; mean tumour size across cohorts; across the non-UVR, + UVR, Placebo + UVR and Dimericine + 
UVR cohorts. Statistically significant results were investigated further using Tukey’s post hoc test. The 
incidence of melanoma development was modelled using Kaplan-Meier analysis, and the log-rank test was 
used to test for pairwise differences between the groups. The statistical significance levels for all tests were 
adjusted for the multiple pairwise comparisons using the Bonferroni method p<0.004.  A three-way ANOVA 
was used to compare the increase in epidermal or extrafollicular melanocytes following UVR. The 
hypothesised difference between treatments was expressed as a contrast of means and tested with the 
associated t-test. Pearson’s Chi squared test was used to compare the number of melanoma cases per animal 
between cohorts. 
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Table 1.  Melanoma penetrance in Cdk4R24C/R24C/NrasQ61K mice. 
 
      
              
NON-UV   33  33%     259 Days            ref           p<0.001*  
+UV   19  100%                 142 Days           p<0.001*            0.1178 
Placebo +UV   20  100%                 178 Days           p<0.001*            0.0115  
Dimericine +UV  13  100%     155 Days           p<0.001*              ref  
Cdk4R24C/R24C/NrasQ61K animals on a FVB background were used in this study. 
^Corrected for multiply pair wise comparisons Bonferroni method p<0.004 for significants 
* denotes statistically significant comparisons.  
All melanoma cases were confirmed by pathologist (HKM). 
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Table 2  Number of Melanoma cases per Animal 
         
              
NON-UV    8   (80%)          2   (20%)   10  
+UV    14   (74%)       5  (26%)   19 
Placebo +UV   13  (65%)       7   (35%)   20  
Dimericine +UV   5   (39%)              8   (61%)   13   
 
1 melanoma 
per animalCohort   
Total number of 
animals 
>1 melanoma 
per animal
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Figure legends 
Figure 1.    Dimericine treatment reduced the level of DNA damage present in the skin following UVR 
exposure.  
A) Graph displaying the average proportion of epidermal cells that contain 6-4 photoproducts 3 h post UVR 
(Mann Whitney p=0.014). B) Line graph displaying the average precentage of epidermal cells that contain 
CPD DNA damage (Mann Whitney 3 hrs post-UVR, p=0.004). At least three animals were used to generate 
each point and all animals used in these figures were genotyped Cdk4R24C/R24C/NrasQ61K. * denotes statistically 
significant comparisons.(error bar= SEM). 
 
Figure 2.    Immunohistochemical images of 6-4 photoproduct, CPD, Ki67 and Tyrp-1 staining in 
mouse skin following UVR exposure.  
A) Placebo treated skin 3 h post UVR with nuclear staining positive (green) for 6-4 photoproducts in the 
epidermis, no melanocytes were identified by Tyrp1 staining (centre image), DAPI (right). B) CPD damage 
was identified by green staining in the nucleus of placebo treated skin. Melanocytes were identified by Tyrp1 
staining (centre image), note the damaged epidermal melanocyte staining above the dotted line for both CPD 
and Tyrp-1 in the overlay image (right). C) Proliferating cell’s nucleus are stained with Ki67 (green) and 
melanocytes identified by cytoplasmic staining with Tyrp1 (centre image). Note the proliferating epidermal 
melanocyte staining above the dotted line in the overlay image (right). D) Placebo treated skin 72 h post 
UVR with cytoplamsic Tyrp1 staining (red) for melanocytes, note the large number of epidermal 
melanocytes (staining above the dotted line).  E) Dimericine treated skin 72 h post UVR with cytoplamsic 
Tyrp1 staining (red) for melanocytes, note the lack of epidermal melanocytes (staining above the dotted 
line).  All sections were counterstained with DAPI (blue). (Scale bar for all images = 10 µm). 
 
 Figure 3. Dimericine treatment and melanocyte proliferation.  
A) Proportion of proliferating epidermal cells at 72 h post UVR exposure. All animals used in this figure 
were genotyped Cdk4R24C/R24C/NrasQ61K (Placebo +UV, n= 3; Dimericine +UV, n= 4; non-UVR, n= 3) 
(ANOVA, p<0.001). B) Line graph displaying the average number of epidermal melanocytes at time points 
following UVR exposure in Cdk4R24C/R24C/NrasQ61K mice (Placebo +UV, 3 h, n= 4; 24 h, n= 3; 72 h, n= 3; 
Dimericine +UV, 3 h, n= 3; 24 h, n= 4; 72 h, n= 4; non-UVR, 3 h, n= 3; 24 h, n= 3; 72 h, n= 5) (ANOVA, 
contrast t test  p<0.01). C) Line graph displaying the average number of extra-follicular dermal melanocytes 
at time points following UVR exposure (ANOVA p<0.01). Figure C used the same number of 
Cdk4R24C/R24C/NrasQ61K animals as in Figure B with the addition of Cdk4R24C/R24C Placebo +UV, 3 h, n= 3; 24 
h, n= 3; 72 h, n= 3; Cdk4R24C/R24C Dimericine +UV, 3 h, n= 2; 24 h, n= 1; 72 h, n= 1; non-UVR, 3 h, n= 2; 24 
h, n= 3; 72 h, n= 2 animals. * denotes statistically significant comparisons. (error bar= SEM). 
 
Figure 4. Melanoma phenotypic characteristics and histological staining of melanoma sections.  
A) Macro image of melanoma (scale bar= 0.5 cm). B) H&E stained section of a cutaneous melanoma (scale 
bar= 100 µm). C) Dermal lesion stained for Tyrp1 (red) (scale bar= 100 µm). D) Tyrp1 stained lesion 
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showing melanocytic clusters along the superficial dermis (scale bar= 100 µm). E) High power image of 
lesion stained for Tyrp1 with melanocytic cells (red) along the basal layer and dermis (scale bar = 50 µm). F) 
Bar graph displaying the average size of all lesions cm2 (error bar= SEM), (n=number of melanoma cases per 
cohort), (ANOVA p=0.37). 
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Supplementary Materials 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Dimericine treatment reduced the level of erythema present in mouse skin following UVR 
exposure.  Skin peeling was observed in animals treated with placebo lotion (left) 72 h post UVR exposure, 
while Dimericine application prior to UVR (centre) protected the skin from peeling. No erythema was 
observed in non-UVR treated animals (right). 
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Figure S2. Dorsal region of mouse skin used in the proliferation and DNA damage assays. The same 
regional area was collected from all animals and sections were cut 50 µm in from the tissue edge for 
immunostaining. 
 
 
 
 
